Last reviewed 2026-04-22 · How we verify

Placebo Formula 515

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule Quality 2/100

Placebo Formula 515 is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Clinical research control comparator, Conditions responsive to placebo effect.

Placebo Formula 515 is an inert formulation with no active pharmaceutical ingredient, producing therapeutic effects through placebo mechanisms.

Placebo Formula 515 is an inert formulation with no active pharmaceutical ingredient, producing therapeutic effects through placebo mechanisms. Used for Clinical research control comparator, Conditions responsive to placebo effect.

At a glance

Generic name	Placebo Formula 515
Sponsor	Assistance Publique - Hôpitaux de Paris
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

As a placebo product, it contains no active drug substance and works through psychobiological mechanisms including expectation, conditioning, and the placebo effect. It is typically used in clinical research as a control comparator or in therapeutic contexts where the ritual of treatment and patient expectation contribute to symptom improvement.

Approved indications

Clinical research control comparator
Conditions responsive to placebo effect

Common side effects

Nocebo effects (adverse events attributed to placebo)

Key clinical trials

Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo Formula 515 CI brief — competitive landscape report
Placebo Formula 515 updates RSS · CI watch RSS
Assistance Publique - Hôpitaux de Paris portfolio CI

Frequently asked questions about Placebo Formula 515

What is Placebo Formula 515?

Placebo Formula 515 is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Clinical research control comparator, Conditions responsive to placebo effect.

How does Placebo Formula 515 work?

Placebo Formula 515 is an inert formulation with no active pharmaceutical ingredient, producing therapeutic effects through placebo mechanisms.

What is Placebo Formula 515 used for?

Placebo Formula 515 is indicated for Clinical research control comparator, Conditions responsive to placebo effect.

Who makes Placebo Formula 515?

Placebo Formula 515 is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What development phase is Placebo Formula 515 in?

Placebo Formula 515 is FDA-approved (marketed).

What are the side effects of Placebo Formula 515?

Common side effects of Placebo Formula 515 include Nocebo effects (adverse events attributed to placebo).

Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
Indication: Drugs for Clinical research control comparator
Indication: Drugs for Conditions responsive to placebo effect

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing